OKYO Pharma (NASDAQ:OKYO) and Immunovant (NASDAQ:IMVT) Head-To-Head Contrast

OKYO Pharma (NASDAQ:OKYO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Valuation & Earnings

This table compares OKYO Pharma and Immunovant”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
Immunovant	N/A	N/A	-$259.34 million	($2.62)	-7.86

Volatility and Risk

OKYO Pharma has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for OKYO Pharma and Immunovant, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
Immunovant	0	1	10	1	3.00

OKYO Pharma currently has a consensus target price of $7.00, indicating a potential upside of 455.60%. Immunovant has a consensus target price of $45.90, indicating a potential upside of 122.82%. Given OKYO Pharma’s higher possible upside, equities research analysts plainly believe OKYO Pharma is more favorable than Immunovant.

Profitability

This table compares OKYO Pharma and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Immunovant	N/A	-77.94%	-69.82%

Insider & Institutional Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 5.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

OKYO Pharma beats Immunovant on 5 of the 9 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.